Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 17/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 0.86 |
| ▸ | DRD4 | P21917 | 1/20 | 0.86 |
| ▸ | DRD3 | P35462 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14164158 | 0.94 | HTR1A (0.89) | HTR1ADRD2DRD4DRD3 | |
| Befiradol SCHEMBL31214695 | 0.93 | HTR1A (1.00) | HTR1ADRD2DRD4DRD3 | |
| SCHEMBL1380782 | 0.93 | HTR1A (0.86) | HTR1ADRD2DRD4DRD3 | |
| Befiradol SCHEMBL29408712 | 0.93 | HTR1A (1.00) | HTR1ADRD2DRD4DRD3 | |
| Befiradol SCHEMBL678174 | 0.93 | HTR1A (1.00) | HTR1ADRD2DRD4DRD3 | |
| Befiradol SCHEMBL4546512 | 0.93 | HTR1A (1.00) | HTR1ADRD2DRD4DRD3 | |
| Befiradol SCHEMBL31214696 | 0.93 | HTR1A (1.00) | HTR1ADRD2DRD4DRD3 | |
| SCHEMBL10066547 | 0.89 | HTR1A (0.79) | HTR1ADRD2DRD4DRD3 | |
| SCHEMBL1378364 | 0.89 | HTR1A (0.86) | HTR1ADRD2DRD4DRD3 | |
| Befiradol SCHEMBL503072 | 0.88 | HTR1A (0.90) | HTR1ADRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0946546-B1 | PYRIDIN-2-YL-METHYLAMINE DERIVATIVES, METHOD OF PREPARING AND APPLICATION AS MEDICINE | PF MEDICAMENT (FR) | 2003-06-25 | — | — | EP | claimed |
| US-8609694-B2 | Use of pyridin-2-yl-methylamine derivatives for the production of a medicament for the treatment of chronic pain symptoms of neuropathological or psychogenic origin | PIERRE FABRE MEDICAMENT (FR) | 2013-12-17 | — | — | US | disclosed |
| EP-1603564-B1 | USE OF PYRIDIN-2-YLMETHYLAMINE DERIVATIVES FOR THE PRODUCTION OF A MEDICAMENT FOR THE TREATMENT OF CHRONIC NEUROPATHOLOGICAL OR PSYCHOGENIC PAIN SYMPTOMS | PF MEDICAMENT (FR) | 2007-07-04 | — | — | EP | disclosed |
| US-20060241141-A1 | Use of pyridin-2-ylmethylamine derivatives for the production of a medicament for the treatment of chronic pain symptoms of neuropathological or psychogenic origin | PIERRE FABRE MEDICAMENT (FR) | 2006-10-26 | — | — | US | disclosed |
| EP-1603564-A2 | USE OF PYRIDIN-2-YLMETHYLAMINE DERIVATIVES FOR THE PRODUCTION OF A MEDICAMENT FOR THE TREATMENT OF CHRONIC NEUROPATHOLOGICAL OR PSYCHOGENIC PAIN SYMPTOMS | PIERRE FABRE MEDICAMENT (FR) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004083171-A2 | USE OF PYRIDIN-2-YLMETHYLAMINE DERIVATIVES FOR THE TREATMENT OF CHRONIC NEUROPATHOLOGICAL OR PSYCHOGENIC PAIN SYMPTOMS | PIERRE FABRE MEDICAMENT (FR) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241141-A1 | Use of pyridin-2-ylmethylamine derivatives for the production of a medicament for the treatment of chronic pain symptoms of neuropathological or psychogenic origin | PNMT, HTR2C, PYGB | HTR1A 20/4885DRD2 394/4885DRD4 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.